Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 65

Interaction of Immune System with Oncolytic Measles Virus Therapy of ...

Medulloblastoma (MB) is the most common malignant brain tumor in children. The Group 3 MB patients have the worst prognosis and dismal 5-year survival rate among the four distinct subtypes of MB: WNT, SHH, Group 3 and Group 4 tumors. Sadly, MB survivors face life-long debilitating neurocognitive side effects from craniospinal radiation that ...

Enhancing response to radiation therapy by increasing tumor oxygenation in ...

The survival time for patients with pediatric high-grade glioma (pHGG) remains devastatingly short, in large part because pHGG tumors become resistant to radiation, the only available therapy with confirmed efficacy. This radioresistance is triggered by regions of hypoxia (low oxygen) that develop within the tumor as it grows. We found ...

Targeting DIPG through combining a super-activator (MCB-613) of steroid receptor ...

The objective of this application is to demonstrate that combining MCB-613, a small molecule stimulator of the oncogenic steroid receptor co-activator (SRC), with ionizing radiation would synergistically kill tumor cells of diffuse intrinsic pontine glioma (DIPG) in vivo and significantly prolong survival times in patient tumor-derived orthotopic (intra-brain stem) xenograft (...

Defining the molecular mechanisms of DIPG development and progression to ...

  Diffuse Intrinsic Pontine Gliomas (DIPGs) are devastating pediatric brainstem tumors that lack effective treatment and are uniformly fatal. Patient studies have identified recurrent genetic lesions that drive the development of these tumors. Almost all DIPGs carry mutations in genes encoding either replication-dependent histone-H3 proteins (mostly HIST1H3B) or ...

An open label single arm phase I/II study of ...

We propose a phase I/limited efficacy clinical trial investigating repeated administration of MTX110, a soluble form of panobinostat, given via convection-enhanced delivery (CED) to pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG). We hypothesize this therapy will be safe and well-tolerated and will be efficacious and prolong ...